Speculation: CYDY/Regeneron partnership for Covid & Long Haulers?
Just for fun (aka pure speculation and perhaps something for this message board to discuss) --
Check out this brief video interview with REGN's CEO (link starts at the 1:47 mark which is the relevant portion):
https://youtu.be/PUKph3PouZg?t=107
I have absolutely no information other than the above linked video and my intuition, which may (most likely) be completely wrong. With that said, some thoughts, just for fun --
First, note the Regeneron CEO's language:
"...We've been searching, our team's been searching, and they found a one in a million antibody, a very very rare antibody, that seems to be able to take care of this virus, neutralize it, in a very potent way, in every known variant to date... and because of some of the technical aspects where it works, we're pretty excited... so we're gonna move very quickly, get it into patients as fast as we can later this year, and hopefully make it available... but unfortunately we actually believe that Covid's gonna be around for a long time, so we are actually thinking this is a long term ability to help patients, and of course that's really our focus."
--Now, a couple of intriguing things to consider:
REGN's CEO says the Regeneron team has "been searching" and "they found a one in a million antibody..." - what's interesting is this sounds to me like maybe they didn't develop this antibody in-house... and I don't know of any monoclonal antibody in existence that fits the description the REGN CEO provided, other than Leronlimab. IF by chance I am correct, my guess is REGN will run a trial (which they obviously have the money and resources to fill rapidly; note their share price is currently over $750) and then hopefully get Leron out there ASAP to start saving lives.
I would think REGN would license the rights from CYDY to all things Covid, including Long Haulers. Also note that CYDY's new CEO Dr. Cyrus Arman indicated something to the effect of (paraphrasing), that although Cydy isn't pursuing Covid at this time, they are open to all opportunities in that lane (REGN partnership?).
Also note that REGN has had their EUA's pulled by the FDA for their variant specific antibodies (their drugs stopped working as Covid mutated), which one would imagine is frustrating for REGN and also financially detrimental, so "finding" an antibody that works for all variants (perhaps Leronlimab) permanently solves that problem for REGN and keeps them in the highly profitable Covid game forever (not to mention Long Covid), without having to constantly develop variant-specific drugs. Leron fits the bill for everything REGN needs, and the interview (perhaps) hints at this fact.
FYI:
"FDA Rescinds Authorization For Covid Antibody Treatments By Regeneron, Eli Lilly" --
https://www.forbes.com/sites/zacharysmith/202...eli-lilly/
Anyway, just my (purely speculative) 2 cents. Hoping to hear what other members of this message board think...
Thanks,
mightyCYDY
Just for fun (aka pure speculation and perhaps something for this message board to discuss) --
Check out this brief video interview with REGN's CEO (link starts at the 1:47 mark which is the relevant portion):
https://youtu.be/PUKph3PouZg?t=107
I have absolutely no information other than the above linked video and my intuition, which may (most likely) be completely wrong. With that said, some thoughts, just for fun --
First, note the Regeneron CEO's language:
"...We've been searching, our team's been searching, and they found a one in a million antibody, a very very rare antibody, that seems to be able to take care of this virus, neutralize it, in a very potent way, in every known variant to date... and because of some of the technical aspects where it works, we're pretty excited... so we're gonna move very quickly, get it into patients as fast as we can later this year, and hopefully make it available... but unfortunately we actually believe that Covid's gonna be around for a long time, so we are actually thinking this is a long term ability to help patients, and of course that's really our focus."
--Now, a couple of intriguing things to consider:
REGN's CEO says the Regeneron team has "been searching" and "they found a one in a million antibody..." - what's interesting is this sounds to me like maybe they didn't develop this antibody in-house... and I don't know of any monoclonal antibody in existence that fits the description the REGN CEO provided, other than Leronlimab. IF by chance I am correct, my guess is REGN will run a trial (which they obviously have the money and resources to fill rapidly; note their share price is currently over $750) and then hopefully get Leron out there ASAP to start saving lives.
I would think REGN would license the rights from CYDY to all things Covid, including Long Haulers. Also note that CYDY's new CEO Dr. Cyrus Arman indicated something to the effect of (paraphrasing), that although Cydy isn't pursuing Covid at this time, they are open to all opportunities in that lane (REGN partnership?).
Also note that REGN has had their EUA's pulled by the FDA for their variant specific antibodies (their drugs stopped working as Covid mutated), which one would imagine is frustrating for REGN and also financially detrimental, so "finding" an antibody that works for all variants (perhaps Leronlimab) permanently solves that problem for REGN and keeps them in the highly profitable Covid game forever (not to mention Long Covid), without having to constantly develop variant-specific drugs. Leron fits the bill for everything REGN needs, and the interview (perhaps) hints at this fact.
FYI:
"FDA Rescinds Authorization For Covid Antibody Treatments By Regeneron, Eli Lilly" --
https://www.forbes.com/sites/zacharysmith/202...eli-lilly/
Anyway, just my (purely speculative) 2 cents. Hoping to hear what other members of this message board think...
Thanks,
mightyCYDY
9
